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OBJECTIVE — Patients with type 1 diabetes and microalbuminuria are at increased risk of
cardiovascular disease (CVD). Abnormalities in vascular progenitor cells, which participate in
vascular repair, may be implicated in this susceptibility.
RESEARCH DESIGN AND METHODS — We studied the number and function of
vascular progenitor cells in 22 type 1 diabetic patients with history of microalbuminuria (MA
)
and 22 type 1 diabetic patients without history of microalbuminuria (MA
), of similar age,
diabetes duration, glycemic control, renal function, and no history of CVD.
RESULTS —M A
 patients had lower circulating CD34
 and CD34
/CD133
 cell numbers
compared with MA
 patients (P  0.006). In in vitro functional assays, MA
 patients had a
signiﬁcantly lower number of colony-forming units and impaired vascular endothelial growth
factor (VEGF)-A–mediated tube formation, when compared with MA
 patients (P  0.01).
CONCLUSIONS — In type 1 diabetic patients with microalbuminuria, a marker of micro-
vascular injury and a risk factor for CVD, circulating vascular progenitor cell number is reduced
and function is impaired.
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T
he number of circulating endothe-
lial progenitor cells inversely relates
to cardiovascular disease (CVD) (1–
3);microalbuminuriaisoneoftheearliest
manifestations of diabetic nephropathy
and a marker of CVD (4). A subset of pa-
tients with type 1 diabetes is susceptible
to diabetic nephropathy, a condition
characterized by a higher risk of cardio-
vascular morbidity and mortality (4,5).
Type 1 diabetic patients without compli-
cations have a lower number of circulat-
ing progenitor cells than healthy control
subjects (6,7). To gain insight into the
susceptibility to CVD in type 1 diabetes,
we studied circulating vascular progeni-
tor cell number and function in type 1
diabetic patients with and without
microalbuminuria.
RESEARCH DESIGN AND
METHODS— Type 1 diabetic pa-
tients were recruited from Guy’s and St
Thomas’ Hospital (London, U.K.). Pa-
tients with microalbuminuria (MA
) had
a positive history of early-morning urine
albumin-to-creatinine ratio (ACR) 3.5
mg/mmol (in at least two of three consec-
utive measures), were on antihyperten-
sivetherapy,andhadevidenceofdiabetic
retinopathy.
Thenormoalbuminuric(MA
)type1
diabetic patients were deﬁned as patients
with 20 years’ diabetes duration, ACR
consistently 3.5 mg/mmol, and on no
antihypertensive therapy.
Exclusion criteria were as follows:
historyofCVD,nondiabeticrenaldisease,
and renal impairment deﬁned as a serum
creatinine 130 mol/l. The study was
approved by the local ethics committee.
Blood pressure, measured in the
dominant arm with the patient seated af-
ter a 5-min rest using an automated
sphygmomanometer (Dinamap-8100T;
GE-Medical, Slough, U.K.), was calcu-
lated from the mean of three consecutive
measurements. Fasting plasma glucose,
serum total cholesterol, and creatinine
were determined using a Cobas-Mira-
Plus analyzer (Roche-Diagnostics, Basel,
Switzerland). A1C was measured by liq-
uid chromatography (Primus-CLC330;
Primus Diagnostic, Kansas City, MO).
Circulating progenitor cells were in-
vestigated as described (3). Leukocytes
were studied from peripheral blood after
red cell lysis with ammonium chloride
buffer. At least 500 CD34
/CD133

events were collected for each patient and
showed 1  10
6 events in the
lymphomonocyte gated area. Intra-assay
coefﬁcientofvariationwas8%.Dataare
presented as events/10
6 lymphomono-
cytes (Fig. 1).
The cell colony–forming units–Hill
(CFU-Hill) assay was performed as de-
scribed (2). For the tube formation assay,
early(7-dayculture)andlate(14-daycul-
ture) endothelial progenitor cells were
studied in the presence and absence of
vascular endothelial growth factor
(VEGF)-A (3,8). Cells were characterized
by immunoﬂuorescence (supplementary
Fig. 1, available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc09-1468/DC1).
Measurements and data analysis
(SPSS-15) were performed blinded to
group allocation. Not-normally and nor-
mally distributed variables were com-
pared by Kruskall-Wallis and Student’s t
test (two-sided), respectively; when more
thantwogroupswerecompared,ANOVA
(least signiﬁcance difference post hoc
test) was used. P  0.05 was considered
statistically signiﬁcant.
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 (17
males/5females)and22MA
(13males/9
females) subjects of Caucasian origin
were studied (P  0.23 for sex between
groups). There were no differences be-
tween the two groups (MA
 vs. MA
)i n
age (mean  SD) 50.3  11.9 vs. 49.8 
6.6 years, diabetes duration 35.2  10.2
vs. 30.9  7.7 years, BMI 25.2  3.4 vs.
27.9  6.3 kg/m
2, A1C 8.1  1.6 vs.
8.3  1.3%, total cholesterol 4.8  0.8
vs. 4.6  0.6 mmol/l, estimated glomer-
ular ﬁltration rate (eGFR–Modiﬁcation of
Diet in Renal Disease formula) 79.3 
23.6 vs. 86.0  27.8 ml/min, systolic
127.515.7vs.125.39.5mmHg,and
diastolic blood pressure 74.7  8 vs.
72.1  7.5 mmHg. All patients had evi-
dence of diabetic retinopathy and eGFR
50 ml/min.
A total of 100% of the MA
 patients
were on ACE inhibitors compared with 0%
inMA
(P0.005).TwentyMA
patients
were on statins compared with 5 MA
 pa-
tients (P  0.05); 5 MA
 a n d4M A
 pa-
tients were smokers.
MA
 patients had signiﬁcantly lower
number of CD34
 and CD34
/CD133

cells when compared MA
; CD34
/
KDR
, CD34
/CD133
/KDR
, and
CD133
/KDR
 cell number was similar
between groups (Fig. 1A and B).
The CFU-Hill assay was conducted in
10 MA
 (6 males/4 females) and 8 MA
 (5
males/3 females) consecutive patients from
thepopulationdescribedcomparableforall
characteristics.Colonyformationwaslower
inMA
(MA
median[interquartilerange],
43 [35–56] vs. MA
 93 [52–103], P 
0.01).
Tube formation experiments were con-
ducted in 9 MA
(5 males/4 females) and 7
MA
 (4 males/3 females) type 1 diabetic
consecutive patients as above. In experi-
ments with early endothelial progenitor
cells, we did not observe differences be-
tween groups. In experiments with late en-
dothelial progenitor cells, we observed a
VEGF-A–mediated increase in tube surface
area only in MA
 patients; MA
 patients
had a signiﬁcantly lower tube number than
MA
 patients (Fig. 1C and D).
CONCLUSIONS — We demonstrated
a lower number of circulating CD34
 and
CD34
/CD133
cellsandCFU-Hillintype
1 diabetic/MA
 patients compared with
type 1 diabetic/MA
 patients. VEGF-A–
mediated in vitro tube formation was ob-
served only in cells derived from MA

Figure 1—Circulating vascular progenitor cell (A and B) and tube formation (C and D) assay in type 1 diabetic patients with and without microalbu-
minuria. Circulating CD34
 and CD34
/CD133
 progenitor cell number was lower in MA
 ( ) versus MA
 (f)( * P  0.006) (A) patients. No
difference was seen in CD34
/CD133
/KDR
, CD34
/KDR
, and CD133
/KDR
 cells (B)( n  22 for MA
; n  22 for MA
, data are presented as
medianandinterquartilerange).Inexperimentsconductedwithlateendothelialprogenitorculturedcells(CandD),surfaceareaoccupiedbycompletetube
perﬁeldwassimilarinMA
andMA
invehicle-treatedcells( ).VEGF-A(f)increasedtubesurfaceformationonlyinMA
(C)patients(MA
/vehicle
vs.MA
/VEGF-A,*P0.016;MA
/VEGF-Avs.MA
/VEGF-A,**P0.003).Tubenumberwassimilarbetweenvehicle( )andVEGF-A–treated(f)
conditions within MA
and MA
groups. MA
patients had a signiﬁcant lower tube number than MA
patients both in vehicle and VEGF-A–treated cells
(MA
/vehicle vs. MA
/vehicle, #P  0.02; MA
/VEGF-A vs. MA
/VEGF-A, **P  0.01) (D). All experiments were conducted in triplicate, and the
average obtained for each patient was used for statistical analysis (n  9 for MA
; n  7 for MA
, data are presented as mean  SD).
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repair processes in MA
 (3).
Microalbuminuria is a strong predictor
forCVDinlongstandingtype1diabeticpa-
tients (5), and in our study, microalbumin-
uria associates with a low number of
circulating progenitor cells, a recognized
marker of CVD.
ACE inhibitors increase the number
and function of vascular progenitor cells
(9); despite a more prevalent use of these
medications in the MA
 group, we still
observe a signiﬁcantly lower number of
CD34
, CD34
/CD133
, and impaired
tube formation in MA
 patients. Con-
versely, the effect of statins on progenitor
cells has been controversial (9,10), and
this may represent a confounder in our
study.
The number of CD34
/KDR
 and
CD34
/CD133
 cells is reduced in hy-
pertensive patients (11); normalization of
blood pressure with renin-angiotensin
system inhibitors is paralleled by normal-
ization of these cells (11). This suggests
that in our type 1 diabetic/MA
 popula-
tion (100% on ACE inhibitors), the ob-
served reduction in CD34
 and CD34
/
CD133
 cells is independent of blood
pressure. Further, we found no correla-
tion between systolic or diastolic blood
pressure and CD34
 and CD34
/
CD133
withintheMA
orMA
groups.
Our observations are in line with the
described inverse relationship between
CD34
cellsandprogressionofnephrop-
athy in type 2 diabetes (12). Indeed,
signiﬁcant renal impairment affects pro-
genitor cell number and function (13);
however, both our groups had relatively
preservedandcomparablerenalfunction,
and we did not observe a correlation be-
tween progenitor cell number and eGFR.
All our patients had retinopathy;
however, its severity was not measured.
The observation that microalbuminuric
diabetic patients have more severe reti-
nopathy (14), a condition paralleled by
higher circulating progenitor cells (15),
could have underestimated the observed
differences.
In conclusion, in a relatively “pro-
tected” population of type 1 diabetic pa-
tients,withorwithoutmicroalbuminuria,
circulating vascular progenitor cells may
be a mean by which individuals respond
to the vascular risk linked with diabetes
and improve their long-term vascular
health,whileothers,unabletorespondto
insults, are at higher risk for renal and
vascular diseases.
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